Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05950646

Mini-dose Dexmedetomidine-Esketamine Infusion and Perioperative Sleep Quality

Conditions: Old Age, Knee Replacement Surgery, Hip Replacement Surgery, Dexmedetomidine, Esketamine, Sleep Quality

Sex: All
Ages: 65 Years – 90 Years
Healthy volunteers: No
Phase: PHASE4
Enrollment: 154
Sponsor: Peking University First Hospital

Location: Beijing Hospital Beijing Beijing Municipality

Summary

Sleep disturbances are prevalent in older patients with osteoarthrosis or fracture who are scheduled for knee or hip replacement surgery. The occurrence of sleep disturbances is associated with worse outcomes including increased risk of delirium and cardiac events, and worsened functional recovery. Dexmedetomidine is a highly selective α2-adrenergic agonist with sedative, anxiolytic, and analgesic properties. It exerts sedative effects via activating the endogenous sleep pathways and produces a state like non-rapid eye movement sleep, which is different from opioid- and benzodiazepine-induced sedation. Esketamine is a N-methyl-D-aspartic acid receptor antagonist and has been used as an anesthetic and analgesic. Recent studies showed that low-dose esketamine has anti-depressive and sleep-promoting effects. The investigators suppose that mini-dose dexmedetomidine-esketamine combined infusion at night can improve perioperative sleep quality in patients scheduled for knee or hip replacement surgery.

Eligibility Criteria

Inclusion Criteria: * Age ≥65 years and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05950646). StuddyBuddy aggregates publicly available trial information.